KLRK1 and cancer: Here, we demonstrated that WEE1 kinase inhibition also sensitized murine and human cancer cells to granzyme B-dependent NK killing independent of MHC class I, PD-L1 or NKG2D ligand expression [29, 30], suggesting that inhibition of cell cycle checkpoint activation may be a more universal approach to sensitizing tumor cells to immunotherapy.